Video

Dr. Raghav on First-Line Treatment Options in CRC

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer.

Kanwal Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses first-line treatment options for patients with colorectal cancer (CRC).

The arsenal for treating patients with CRC includes cytotoxic chemotherapy, targeted agents, immunotherapy, and some treatments specifically for use in the salvage-line settings, according to Raghav. Additionally, molecular profiling should be done up front for patients with metastatic disease, as it significantly changes their standard-of-care management, and can help prepare them for future treatment strategies, including clinical trials, Raghav says.

Generally, immunotherapy, such as pembrolizumab (Keytruda), is recommended up front for patients with mismatch repair deficient or microsatellite instability–high CRC, Raghav notes. In the larger subset of patients with mismatch repair proficient disease, those who harbor a RAS mutations have limited treatment options. As such, these patients are often treated with cytotoxic chemotherapy and anti-VEGF agents such as bevacizumab (Avastin) in the first-line setting, Raghav concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity